2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow VT-464: new trials by email Literature Review of VT-464 trials Research Report on VT-464
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer VT-464: given orally once daily in 28 day cycles - Castration-resistant Prostate Cancer, CRPC | Phase 1 / Phase 2 | Completed | Innocrin Pharmaceutical | 21 | 2014-06-01 | 2019-02-01 |
| Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles - Prostate Cancer | Phase 2 | Completed | Innocrin Pharmaceutical | 17 | 2014-04-01 | 2018-05-07 |
Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
United States (2)
Joel Eisner (1)